Fusion molecules and IL-15 variants

Patent metadata

Field	Value
Publication number	US-12168680-B2
Application number	US-202318305965-A
Country	US
Kind code	B2
Filing date	Apr 24, 2023
Priority date	May 11, 2007
Publication date	Dec 17, 2024
Grant date	Dec 17, 2024

Abstract

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

First claim

What is claimed is:

1. A method of treatment for cancer or viral infection in a mammal in need thereof, the method comprising administering an effective amount of a soluble fusion protein complex comprising two soluble proteins, wherein the first soluble protein comprises:
(a) a fusion protein comprising a first biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide, or
(b) an IL-15 polypeptide; and
the second soluble protein comprises a fusion protein comprising:
(c) a second biologically active polypeptide covalently linked to (d) an interleukin-15 receptor alpha (IL-15Ra) polypeptide;
wherein the first and/or second biologically active polypeptides comprise cytokines, chemokines, growth factors or receptor binding domains thereof;
wherein the IL-15 domain of the first soluble protein binds to the IL-15Ra domain of the second soluble protein to form the soluble fusion protein complex; and
wherein the first biologically active polypeptide is different than an IL-15Ra polypeptide, and the second biologically active polypeptide is different than an IL-15 polypeptide.

2. The method of claim 1 , wherein the first and/or second biologically active polypeptides comprises a cytokine or a binding partner thereof.

3. The method of claim 2 , wherein the cytokine comprises TGF-beta (TGF-β), or a binding partner thereof.

4. The method of claim 1 , wherein the first biologically active polypeptide is covalently linked to the IL-15 polypeptide by a polypeptide linker sequence.

5. The method of claim 1 , wherein the second biologically active polypeptide is covalently linked to the IL-15Ra polypeptide by a polypeptide linker sequence.

6. The method of claim 1 , wherein the IL-15Ra polypeptide comprises the extracellular domain of the IL-15 receptor alpha that binds the IL-15 polypeptide.

7. The method of claim 1 , wherein the IL-15Ra polypeptide comprises either the IL-15a sushi domain or the IL-15Ra delta E3 (IL-15aΔE3) domain.

8. The method of claim 1 wherein the mammal is suffering from cancer and the administering treats cancer in the mammal.

9. The method of claim 1 wherein the mammal is suffering from a viral infection and the administering treats the viral infection in the mammal.

10. The method of claim 9 , wherein the mammal is suffering from a human immunodeficiency virus (HIV) infection.

11. The method of claim 1 , wherein at least one of the first and second biologically active polypeptides recognizes a disease-associated antigen.

12. The method of claim 11 , wherein the disease-associated antigen is a peptide/MHC complex.

13. The method of claim 1 , wherein at least one of the first and second biologically active polypeptides comprises an antibody or binding fragment thereof.

14. The method of claim 1 , wherein the administering results in forming a specific binding complex between antigen-expressing diseased cells and IL-15R-expressing immune cells sufficient to localize the immune cells, and sufficiently damaging or killing the disease cells in order to prevent or treat the disease in the mammal.

15. The method of claim 1 , wherein at least one of the first and second biologically active polypeptides increases the in vivo half-life of the soluble fusion protein complex.

16. The method of claim 1 , wherein the soluble fusion protein complex is administered via oral, topical, nasal, or parenteral route.

17. The method of claim 1 , wherein the soluble fusion protein complex is formulated as a pharmaceutical composition for administration to the mammal in need thereof.

Assignees

• Altor Bioscience Llc

Inventors

• Wong Hing C
• Rhode Peter
• Zhu Xiaoyun
• Han Kai-Ping

Classifications

• A61K38/1793

  for cytokines; for lymphokines; for interferons · CPC title

• A61K38/1774

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title

• G01N33/56977

  HLA or MHC typing · CPC title